Gilead Sciences, Inc. Press Releases https://investors.gilead.com/generated by Q4Thu, 22 Oct 2026 16:06:26 -0400Copyright Q4 Inc. All rights reserved.Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD8ca20fb1-49ad-4242-a973-fcd1493f559bhttps://investors.gilead.com/news/news-details/2026/Gilead-to-Acquire-Investigational-Oral-IL-23R-Inhibitor-HCXT-2001-Strengthening-Its-Inflammation-Pipeline-in-IBD/default.aspxThu, 22 Oct 2026 16:05:00 -0400Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 20263ed5dfa5-ded0-49fc-a9d6-efdddbfcdc54https://investors.gilead.com/news/news-details/2026/Gilead-to-Present-New-Data-on-Treatment-Response-and-Long-Term-Management-of-Rare-Liver-Diseases-at-The-Liver-Meeting-2026/default.aspxThu, 22 Oct 2026 08:00:00 -0400Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026a9bb0a9e-920f-422f-94a8-4105d7ce8150https://investors.gilead.com/news/news-details/2026/Gilead-to-Present-New-Data-Across-HIV-and-Emerging-Antiviral-Research-at-IDWeek-2026/default.aspxMon, 19 Oct 2026 08:00:00 -0400Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026c056a8d2-f6be-4d80-a530-6889ee890912https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-to-Release-Third-Quarter-2026-Financial-Results-on-Thursday-October-29-2026/default.aspxThu, 15 Oct 2026 16:05:00 -0400Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Preventionb40345f7-c1dc-44a9-8a40-1331b50e65d5https://investors.gilead.com/news/news-details/2026/Gilead-Accelerates-Global-Access-Planning-for-Investigational-Once-Yearly-Lenacapavir-for-HIV-Prevention/default.aspxWed, 16 Sep 2026 08:30:00 -0400Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean30bf2b67-dc44-47ea-bf3c-5666d1dcfdbbhttps://investors.gilead.com/news/news-details/2026/Gilead-and-PAHO-Announce-Milestone-Partnership-to-Accelerate-Access-to-Twice-Yearly-Lenacapavir-for-HIV-Prevention-Across-Latin-America-and-the-Caribbean/default.aspxTue, 15 Sep 2026 11:10:00 -0400Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicinescd8131b1-8ec5-446d-a204-0c6ca840dc3fhttps://investors.gilead.com/news/news-details/2026/Gilead-Opens-State-of-the-Art-Research-Center-to-Advance-the-Next-Generation-of-Medicines/default.aspxTue, 08 Sep 2026 13:00:00 -0400U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens93817b5f-148d-450d-98a4-729cf22dcacehttps://investors.gilead.com/news/news-details/2026/U-S--FDA-Approves-Gileads-Bixlenvo-a-New-Once-Daily-Single-Tablet-Option-for-Virologically-Suppressed-Adults-With-HIV-Including-Those-on-Complex-Regimens/default.aspxThu, 27 Aug 2026 17:47:00 -0400Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences2f6b445a-3883-41e2-96b9-3c09fea88626https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-to-Present-at-Upcoming-Third-Quarter-2026-Investor-Conferences/default.aspxWed, 26 Aug 2026 16:05:00 -0400European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status15ceea32-c8e6-4d27-8652-1e1c70f02fb0https://investors.gilead.com/news/news-details/2026/European-Commission-Expands-Role-of-Gileads-Trodelvy-in-First-Line-Metastatic-Triple-Negative-Breast-Cancer-Across-PD-L1-Status/default.aspxMon, 24 Aug 2026 06:31:00 -0400